Companies / DRTS
Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Ticker DRTS Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $1.06B 52-week range $3.43 - $15.79
Valuation Share price $12.01 (close of Nov 18, 2026) P/E (TTM) -22.66x Price to book 13.71x Price to free cash flow -32.27x Enterprise value $993.82M Book value per share $0.88
Price performance Period Change 1 day -0.66% 5 days -14.34% 1 month -2.28% 3 months -15.78% 6 months +19.74% Year to date +142.63% 1 year +226.36% 3 years +293.77% 5 years +21.19% All time +18.91%
Short interest As of Oct 30, 2026 Short % of float 6.12% Shares short 3.92M Days to cover 8.10 Change since prior report +14.06% Source FINRA consolidated short interest
Profitability and growth Return on equity -55.29% Return on invested capital -46.56% Return on assets -40.35% Return on capital employed -44.45%
Cash flow and balance sheet Free cash flow yield (TTM) -3.10% Current ratio 7.45x Net debt to EBITDA 1.54x
Latest reported year Period end Dec 31, 2025 Fiscal year 2025 EBITDA -$41.06M Net income -$42.63M Earnings per share $-0.53 Research and development $32.06M Interest expense $347.00K Shares outstanding 80.58M
Income statement by year Period end Net income EPS 2025-12-31 -$42.63M -$0.53 2024-12-31 -$31.75M -$0.45 2023-12-31 -$29.16M -$0.42 2022-12-31 -$33.76M -$0.53 2021-12-31 -$27.27M -$0.67 2020-12-31 -$8.88M -$0.22 2019-12-31 -$8.37M -$0.25
Margins and returns by year Period end Return on equity Return on capital 2025-12-31 -55.29% -46.56% 2024-12-31 -50.67% -47.93% 2023-12-31 -34.52% -36.50% 2022-12-31 -31.95% -28.99%
Cash and debt by year Period end Cash 2025-12-31 $76.90M 2024-12-31 $62.85M 2023-12-31 $84.94M 2022-12-31 $104.53M 2021-12-31 $31.32M 2020-12-31 $15.60M
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$32.76M $10.62M 2024-12-31 -$22.02M $9.92M 2023-12-31 -$24.36M $7.93M 2022-12-31 -$24.78M $6.75M 2021-12-31 -$14.74M $812.00K 2020-12-31 -$11.02M $596.00K 2019-12-31 -$8.20M $546.00K
Investor relations Next earnings report Next confirmed report Nov 19, 2026 Consensus EPS estimate $-0.15 Past earnings dates Reported Fiscal period EPS estimate 2026-08-10 Jun 2026 -$0.14 2026-05-18 Mar 2026 -$0.13 2026-03-09 Dec 2025 -$0.13 2025-11-20 Sep 2025 -$0.12 2025-08-11 Jun 2025 -$0.12 2025-05-19 Mar 2025 -$0.14 2025-03-12 Dec 2024 -$0.13 2024-11-19 Sep 2024 -$0.13
Filings and sources Company website alphatau.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports
Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades